Abstract:Abstract A major hurdle in the treatment of inflammatory bowel disease (IBD) is the lack of effective drug carriers that can precisely deliver the required amount of drug to the sites of inflammation. Available therapies have limited efficacy or severe side effects, largely because of the low concentration of active drugs at the disease sites and non-specific systemic absorption of the administered drugs. Drug delivery targeting the sites of intestinal inflammation offers an approach to maximize therapeutic efficacy while minimizing adverse side effects. We focus on developing formulations that can provide improved local drug administration in the treatment of ulcerative colitis (UC), one of the two main types of IBD. Targeting sites of inflammation in the gastrointestinal tract can be achieved using drug delivery systems that exploit pathophysiological features of the inflamed intestine. Our previous study showed preferential adhesion of a negatively charged small-molecule-based hydrogel to the inflamed colon in murine models of colitis and biopsies from UC patients; further, a corticosteroid drug delivered by this hydrogel demonstrated an improved efficacy compared to the drug alone. Based on our previous experience, we expanded the small-molecule-based hydrogel to polymer-based hydrogels for enhanced selective targeting. We designed the material so that it has a strong affinity towards ulcers. Through molecular structure design, we functionalized thermo-responsive poly(N-isopropylacrylamide) (PNIPAM)-based polymers to modulate the physicochemical properties of the materials and compared the resultant polymers’ gelation and adhesion to the inflamed colon in dextran sulfate sodium (DSS)-induced colitis in mice. We showed that both the types of chemical modification and polymer molecular weight affected the adhesion of the resultant hydrogels to the inflamed colon. We further quantified the disease parameters of colitis for individual mice and correlated the colitis parameters with polymers’ adhesion. Our study suggests a new strategy for targeting the inflamed colon through harnessing charge-mediated interaction and thermo-responsiveness of PNIPAM-based polymers. By adhering to the inflamed mucosa, our delivery system has the potential to maintain the drug locally at the active ulcer sites where it is needed, thereby minimizing the adverse effects of drugs on the healthy tissue. The examination of these polymeric hydrogels’ mucosal binding provides a further understanding of interactions between the polymers and the biological interface in colitis. These studies were performed in preclinical models of UC that develop colitis similar to human UC, as a prerequisite for future studies.

Recent advances in nanocarrier systems for ulcerative colitis: A new era of targeted therapy and biomarker integration

Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives

Strategies and opportunities of micro/nano delivery systems for targeted therapy of ulcerative colitis: Focus on underlying mechanisms and future perspectives

Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives

Dual-Sensitive Carbohydrate-Based Nanosystem for Targeted Drug Delivery to Potentiate the Therapeutic Efficacy of Ulcerative Colitis

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Advances in carbohydrate-based nanoparticles for targeted therapy of inflammatory bowel diseases: A review

Nanoparticle-based therapeutics of inflammatory bowel diseases: a narrative review of the current state and prospects

Application of chitosan as nano carrier in the treatment of inflammatory bowel disease

POLYMER-BASED INTERFACE TARGETING INFLAMMATION IN ULCERATIVE COLITIS

Dual‐Targeted Nanoparticle‐In‐Microparticle System for Ulcerative Colitis Therapy

Application of Polymers as Drug Nanocarriers in the Oral Treatment of Ulcerative Colitis

Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease

Nanotechnology for Targeted Inflammatory Bowel Disease Therapy: Challenges and Opportunities

Reactive Oxygen Species-Responsive Polyether Micelle Nanomaterials for Targeted Treatment of Ulcerative Colitis

Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease

Oral Nano-Delivery Systems for Colon-Targeted Drug Delivery of Traditional Chinese Medicine in Ulcerative Colitis

Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy

A Biomarker‐Responsive Nanosystem with Colon‐Targeted Delivery for Ulcerative Colitis's Detection and Treatment with Optoacoustic/NIR‐II Fluorescence Imaging

Current trends and future perspectives of natural polymer loaded nanoparticle based drug delivery system for the management of inflammatory bowel disease

Cell membrane nanomaterials composed of phospholipids and glycoproteins for drug delivery in inflammatory bowel disease: A review